Since the start of the fight against the COVID-19 pandemic, the Russian Direct Investment Fund has been in favor of active coordination with all partners, including from Europe, and open to negotiations, said the organization’s chief executive Kirill Dmitriev today.
The RDIF has already reached agreements with companies from Italy, Spain, France and Germany to launch production of its vaccine Sputnik V. Currently there are additional talks ongoing to boost production in the European Union. This will allow to start supplying Sputnik V to the European single market once the approval is granted by the European Medicines Agency (EMA).
“We are now actively working with EMA as part of the rolling review procedure. In addition, RDIF and partners are ready to start supplies to those EU countries that independently authorize Sputnik V,” said Mr Dmitriev.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze